Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer von Schmidt, M., Rüttinger, D., Sebastian, M., Hanusch, C.A., Marschner, N., Baeuerle, P.A., Wolf, A., Göppel, G., Oruzio, D., Schlimok, G., Steger, G.G., Wolf, C., Eiermann, W., Lang, A., Schuler, M.

Volltext